Electra Therapeutics, Inc. (ETRA)
Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE
What they're doing
Between 2026-08-02 and 2026-10-31, public records show 4 signals for Electra Therapeutics, Inc.. Most notable: 2026-09-21: GORDON CARL L (director) bought $15.0M of stock; 2026-09-21: ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC (director) bought $15.0M of stock; 2026-09-21: GORDON CARL L (director) bought $5.0M of stock. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-10-31 from public records.
Signals, last 12 months
- Insider purchaseORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC (director) bought $15.0M of stock
- Insider purchaseGORDON CARL L (director) bought $15.0M of stock
- Insider purchaseORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC (director) bought $5.0M of stock
- Insider purchaseGORDON CARL L (director) bought $5.0M of stock
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-21 | Koe Gary S. | officer | C | 63,656 | — | — |
| 2026-09-21 | Stagliano Nancy | director | C | 255,635 | — | — |
| 2026-09-21 | Parry Graham | officer | C | 85,504 | — | — |
| 2026-09-21 | Dong Quehuong (Kathy) | director | C | 455,484 | — | — |
| 2026-09-21 | GORDON CARL L | director | C | 2,002,310 | — | — |
| 2026-09-21 | GORDON CARL L | director | C | 1,087,934 | — | — |
| 2026-09-21 | GORDON CARL L | director | C | 1,703,314 | — | — |
| 2026-09-21 | GORDON CARL L | director | P | 333,333 | 15 | $4,999,995 |
| 2026-09-21 | GORDON CARL L | director | C | 758,279 | — | — |
| 2026-09-21 | GORDON CARL L | director | P | 1,000,000 | 15 | $15,000,000 |
| 2026-09-21 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | director | C | 2,002,310 | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | director | C | 1,087,934 | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | director | C | 1,703,314 | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | director | P | 333,333 | 15 | $4,999,995 |
| 2026-09-21 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | director | C | 758,279 | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | director | P | 1,000,000 | 15 | $15,000,000 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.
Recent filings
- 2026-10-29 SCHEDULE 13G
- 2026-09-28 SCHEDULE 13G
- 2026-09-28 SCHEDULE 13G
- 2026-09-25 SCHEDULE 13D
- 2026-09-23 4
- 2026-09-23 4
- 2026-09-21 3
- 2026-09-21 4
- 2026-09-21 4
- 2026-09-21 4
- 2026-09-21 4
- 2026-09-21 S-8
- 2026-09-21 8-K
- 2026-09-18 424B4
- 2026-09-18 3
- 2026-09-18 3
- 2026-09-18 3
- 2026-09-18 3
- 2026-09-18 3
- 2026-09-18 3